kynurenine has been researched along with Depression, Involutional in 90 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alteration of tryptophan (TRP) metabolism elicited by proinflammatory cytokines has gained attention as a new concept to explain the etiological and pathophysiological mechanisms of major depression." | 8.84 | A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. ( Isobe, K; Miura, H; Nagatsu, T; Ohta, T; Ozaki, N; Sawada, M, 2008) |
| " Studies have shown that both stress and MDD, especially the more severe conditions of the disorder, are associated with inflammation and neuroinflammation and the relationship to an imbalance in tryptophan metabolism towards the kynurenine pathway (KP) through the enzymes indoleamine-2,3-dioxygenase (IDO), which is mainly stimulated by pro-inflammatory cytokines and tryptophan-2,3-dioxygenase (TDO) which is activated primarily by glucocorticoids." | 8.31 | Stress and Kynurenine-Inflammation Pathway in Major Depressive Disorder. ( Bertollo, AG; de Oliveira, T; Ignácio, ZM; Mingoti, MED, 2023) |
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 8.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "Kynurenine pathway, a neuroimmunological pathway plays a substantial role in depression." | 8.12 | Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies. ( Bansal, Y; Bishnoi, M; Dhingra, N; Dhingra, R; Khare, P; Kondepudi, KK; Kuhad, A; Singh, R; Sodhi, RK, 2022) |
| "To investigate the relationship between the tryptophan-kynurenine (TRP-KYN) pathway and painful physical symptoms (PPS) in major depressive disorder (MDD)." | 8.12 | Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder. ( An, H; Bai, L; Fan, H; Ma, B; Ma, T; Qi, S; Wang, Z; Yang, F; Yun, Y; Zhang, Q; Zhao, W, 2022) |
| "Tryptophan catabolites ("TRYCATs") produced by the kynurenine pathway (KP) may play a role in depression pathophysiology." | 8.02 | The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation. ( Allers, KA; Beekman, ATF; Giltay, EJ; Keller, S; Milaneschi, Y; Niessen, HG; Penninx, BWJH; Schoevers, RA; Süssmuth, SD, 2021) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 8.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 6.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| "Major depression is a serious psychiatric disorder, occurring in up to 20 % of the population." | 6.72 | The kynurenine pathway in major depression: What we know and where to next. ( Brown, SJ; Huang, XF; Newell, KA, 2021) |
| "Considerable data relate major depressive disorder (MDD) with aberrant immune system functioning." | 5.72 | Peripheral and central kynurenine pathway abnormalities in major depression. ( Asratian, A; Boda, S; Dantzer, R; Erhardt, S; Hamilton, JP; Heilig, M; Holm, L; Kämpe, R; Paul, ER; Samuelsson, M; Schwieler, L; Trepci, A; Yngve, A, 2022) |
| "Future research on the cerebral cell-type specific distribution of kynurenine metabolites and their brain-regional concentration imbalances will be required to connect peripheral immune changes, the hypotheses of blood-brain barrier dysfunction and glial pathology with concepts of altered neurotransmission in schizophrenia and major depression." | 4.88 | Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. ( Bernstein, HG; Bogerts, B; Gos, T; Myint, AM; Sarnyai, Z; Steiner, J; Walter, M, 2012) |
| "Alteration of tryptophan (TRP) metabolism elicited by proinflammatory cytokines has gained attention as a new concept to explain the etiological and pathophysiological mechanisms of major depression." | 4.84 | A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression. ( Isobe, K; Miura, H; Nagatsu, T; Ohta, T; Ozaki, N; Sawada, M, 2008) |
| " Studies have shown that both stress and MDD, especially the more severe conditions of the disorder, are associated with inflammation and neuroinflammation and the relationship to an imbalance in tryptophan metabolism towards the kynurenine pathway (KP) through the enzymes indoleamine-2,3-dioxygenase (IDO), which is mainly stimulated by pro-inflammatory cytokines and tryptophan-2,3-dioxygenase (TDO) which is activated primarily by glucocorticoids." | 4.31 | Stress and Kynurenine-Inflammation Pathway in Major Depressive Disorder. ( Bertollo, AG; de Oliveira, T; Ignácio, ZM; Mingoti, MED, 2023) |
| "Evidence, largely obtained from peripheral studies, suggests that alterations in the kynurenine pathway contribute to the aetiology of depression and disorders involving psychosis." | 4.12 | Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology. ( Brown, AM; Brown, SJ; Huang, XF; Newell, KA; Purves-Tyson, TD; Shannon Weickert, C, 2022) |
| "Kynurenine pathway, a neuroimmunological pathway plays a substantial role in depression." | 4.12 | Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies. ( Bansal, Y; Bishnoi, M; Dhingra, N; Dhingra, R; Khare, P; Kondepudi, KK; Kuhad, A; Singh, R; Sodhi, RK, 2022) |
| "To investigate the relationship between the tryptophan-kynurenine (TRP-KYN) pathway and painful physical symptoms (PPS) in major depressive disorder (MDD)." | 4.12 | Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder. ( An, H; Bai, L; Fan, H; Ma, B; Ma, T; Qi, S; Wang, Z; Yang, F; Yun, Y; Zhang, Q; Zhao, W, 2022) |
| "Tryptophan catabolites ("TRYCATs") produced by the kynurenine pathway (KP) may play a role in depression pathophysiology." | 4.02 | The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation. ( Allers, KA; Beekman, ATF; Giltay, EJ; Keller, S; Milaneschi, Y; Niessen, HG; Penninx, BWJH; Schoevers, RA; Süssmuth, SD, 2021) |
| " We evaluated the relationships between total score on the Montgomery-Åsberg Depression Rating Scale and kynurenine, tryptophan, anthranilic acid and kynurenic acid concentrations, IDO activity and tryptophan availability to the brain." | 4.02 | The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin. ( Bugajska, J; Inglot, M; Janocha-Litwin, J; Malyszczak, K; Marciniak, D; Pawlak, D; Pawlowski, T; Zalewska, M, 2021) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 4.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| " Evidence suggests that the kynurenine (KYN) pathway may be implicated in the pathophysiology of depression, but few studies have explored the association between the KYN pathway and cognitive impairment in MDD." | 3.91 | Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder. ( Chen, L; Li, H; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2019) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Our results suggest that an imbalance between HPA axis function and tryptophan metabolism could be involved in recurrent depression." | 3.85 | The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls. ( de Jonge, P; Doornbos, B; Kema, IP; Penninx, BWJH; Sorgdrager, FJH, 2017) |
| "Several studies have suggested that induced tryptophan (TRP) degradation through the kynurenine (KYN) pathway by the enzyme indoleamine 2,3-dioxygenase (IDO) is implicated in the relation between depression and inflammation." | 3.80 | Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms? ( de Jonge, P; Doornbos, B; Duivis, HE; Kema, IP; Nolen, WA; Penninx, BW; Quak, J; Roest, AM; Vogelzangs, N, 2014) |
| "Major depressive disorder is the most common type of mental disorder." | 3.01 | Effects of exercise training on inflammatory, neurotrophic and immunological markers and neurotransmitters in people with depression: A systematic review and meta-analysis. ( Alt, R; da Cunha, LL; Feter, N; Rombaldi, AJ, 2023) |
| "Major depression is a serious psychiatric disorder, occurring in up to 20 % of the population." | 2.72 | The kynurenine pathway in major depression: What we know and where to next. ( Brown, SJ; Huang, XF; Newell, KA, 2021) |
| "Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients." | 2.72 | Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review. ( Kopra, E; Mondelli, V; Nikkheslat, N; Pariante, C, 2021) |
| "During stress and major depressive disorders, it is generally accepted that inflammation induces an imbalance toward the excitotoxic branch of the TRY/CAT pathway, causing changes in brain connectivity in corticolimbic structures and therefore psychocognitive abnormalities." | 2.61 | The 'Yin' and the 'Yang' of the kynurenine pathway: excitotoxicity and neuroprotection imbalance in stress-induced disorders. ( Barone, P, 2019) |
| "However, gut microbiota changes in major depressive disorder (MDD) patients and their association with disease mechanisms remain undefined." | 1.91 | Dysbiosis of the Gut Microbiota and Kynurenine (Kyn) Pathway Activity as Potential Biomarkers in Patients with Major Depressive Disorder. ( Chen, Q; Chen, S; Cheng, X; Dong, K; Guo, X; Jin, W; Li, D; Li, P; Li, Q; Li, Z; Lin, P; Lou, X; Shi, Y; Sun, J; Sun, Y, 2023) |
| "Considerable data relate major depressive disorder (MDD) with aberrant immune system functioning." | 1.72 | Peripheral and central kynurenine pathway abnormalities in major depression. ( Asratian, A; Boda, S; Dantzer, R; Erhardt, S; Hamilton, JP; Heilig, M; Holm, L; Kämpe, R; Paul, ER; Samuelsson, M; Schwieler, L; Trepci, A; Yngve, A, 2022) |
| "The biological mechanisms underlying major depressive disorder (MDD) are not yet sufficiently understood." | 1.62 | The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder. ( Aydemir, Ö; Kandemir, H; Öztürk, M; Taneli, F; Yalın Sapmaz, Ş, 2021) |
| "The response of patients with major depressive disorders (MDD) to antidepressant treatments have been shown to be affected by multiple factors, including disease severity and inflammation." | 1.56 | The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine. ( Drevets, W; Li, QS; Sun, Y; Turecki, G, 2020) |
| "Recent blood biomarker studies for major depressive disorder (MDD) have suggested that tryptophan-kynurenine and lipid related metabolites are involved in the pathophysiology of MDD." | 1.48 | Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study. ( Hayakawa, K; Kanba, S; Kang, D; Kato, TA; Kishimoto, J; Kubo, H; Kuwano, N; Ohgidani, M; Sagata, N; Sato-Kasai, M; Setoyama, D; Shimokawa, N, 2018) |
| "As chronic inflammation is known to precipitate increased apoptosis of neurons and astrocytes, this could be a contributing factor to brain dysfunction." | 1.46 | Major Depression as a Neuroprogressive Prelude to Dementia: What Is the Evidence? ( Leonard, BE, 2017) |
| "Mastocytosis is a rare disease in which chronic symptoms, including depression, are related to mast cell accumulation and activation." | 1.43 | Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. ( Alyanakian, MA; Aouba, A; Bachmeyer, C; Barète, S; Bonin, B; Chandesris, MO; Chauvet-Gelinier, JC; Côté, F; Damaj, G; Dubreuil, P; Gaillard, R; Georgin-Lavialle, S; Grandpeix-Guyodo, C; Haffen, E; Hermine, O; Launay, JM; Lortholary, O; Moura, DS; Salvador, A; Soucié, E; Teyssier, JR; Trojak, B; Vandel, P, 2016) |
| "Cytokines in plasma from patients with major depressive disorder (MDD; n = 19) and healthy volunteers (n = 14) were analyzed with electrochemiluminescence detection." | 1.43 | Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. ( Bhat, M; Erhardt, S; Frye, MA; Johansson, AG; Jungholm, O; Landén, M; Samuelsson, M; Schuppe-Koistinen, I; Schwieler, L; Sellgren, CM, 2016) |
| "A consistent finding in major depressive disorder (MDD) research is dysfunction of the immune system." | 1.37 | The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes. ( Baune, B; Claes, S; De Deyn, P; Del-Favero, J; Domschke, K; Engelborghs, S; Entrich, K; Mueller, N; Myint, AM; Rothermundt, M, 2011) |
| "Inflammation has been linked to depression and suicide risk." | 1.37 | Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. ( Fuchs, D; Galfalvy, HC; Grunebaum, MF; Lapidus, M; Mann, JJ; Oquendo, MA; Postolache, TT; Sublette, ME, 2011) |
| "Although adolescent major depressive disorder (MDD) is acknowledged to be a heterogeneous disorder, no studies have reported on biological correlates of its clinical subgroups." | 1.36 | The possible role of the kynurenine pathway in adolescent depression with melancholic features. ( Alonso, CM; Babb, JS; Gabbay, V; Guttman, LE; Hirsch, GS; Katz, Y; Klein, RG; Liebes, L; Mendoza, S, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (5.56) | 29.6817 |
| 2010's | 44 (48.89) | 24.3611 |
| 2020's | 41 (45.56) | 2.80 |
| Authors | Studies |
|---|---|
| Messaoud, A | 1 |
| Rym, M | 1 |
| Wahiba, D | 1 |
| Neffati, F | 1 |
| Najjar, MF | 1 |
| Gobbi, G | 1 |
| Manchia, M | 1 |
| Valtorta, F | 2 |
| Lotfi, G | 1 |
| Comai, S | 2 |
| Bou Khalil, R | 1 |
| El Khoury, R | 1 |
| Melloni, E | 1 |
| Lorenzi, C | 1 |
| Bollettini, I | 1 |
| Vai, B | 1 |
| Zanardi, R | 1 |
| Colombo, C | 1 |
| Benedetti, F | 2 |
| Poletti, S | 2 |
| Paul, ER | 1 |
| Schwieler, L | 2 |
| Erhardt, S | 2 |
| Boda, S | 1 |
| Trepci, A | 1 |
| Kämpe, R | 1 |
| Asratian, A | 1 |
| Holm, L | 1 |
| Yngve, A | 1 |
| Dantzer, R | 6 |
| Heilig, M | 1 |
| Hamilton, JP | 1 |
| Samuelsson, M | 2 |
| Brown, SJ | 2 |
| Brown, AM | 1 |
| Purves-Tyson, TD | 1 |
| Huang, XF | 2 |
| Shannon Weickert, C | 1 |
| Newell, KA | 2 |
| Mingoti, MED | 2 |
| Bertollo, AG | 2 |
| Simões, JLB | 1 |
| Francisco, GR | 1 |
| Bagatini, MD | 1 |
| Ignácio, ZM | 2 |
| Wang, L | 3 |
| Yang, P | 1 |
| Yang, C | 2 |
| Yang, D | 1 |
| Wu, X | 1 |
| Cao, T | 1 |
| Zeng, C | 1 |
| Chen, Q | 2 |
| Zhang, S | 1 |
| Zhu, Z | 1 |
| Jiao, S | 1 |
| Cai, H | 1 |
| Dawood, S | 1 |
| Bano, S | 1 |
| Badawy, AA | 1 |
| Kamishikiryo, T | 1 |
| Okada, G | 1 |
| Itai, E | 1 |
| Masuda, Y | 1 |
| Yokoyama, S | 1 |
| Takamura, M | 1 |
| Fuchikami, M | 1 |
| Yoshino, A | 1 |
| Mawatari, K | 1 |
| Numata, S | 1 |
| Takahashi, A | 1 |
| Ohmori, T | 1 |
| Okamoto, Y | 1 |
| Bansal, Y | 1 |
| Singh, R | 1 |
| Sodhi, RK | 1 |
| Khare, P | 1 |
| Dhingra, R | 1 |
| Dhingra, N | 1 |
| Bishnoi, M | 1 |
| Kondepudi, KK | 1 |
| Kuhad, A | 1 |
| Zheng, H | 1 |
| Teague, TK | 6 |
| Yeh, FC | 1 |
| Burrows, K | 1 |
| Figueroa-Hall, LK | 1 |
| Aupperle, RL | 1 |
| Khalsa, SS | 1 |
| Paulus, MP | 2 |
| Savitz, J | 6 |
| Gong, X | 1 |
| Chang, R | 1 |
| Zou, J | 1 |
| Tan, S | 1 |
| Huang, Z | 2 |
| Wei, J | 1 |
| Zhang, Z | 1 |
| Du, Y | 1 |
| Yang, X | 1 |
| Zhao, L | 1 |
| Ni, P | 1 |
| Ni, R | 1 |
| Gong, M | 1 |
| Ma, X | 1 |
| Davidson, M | 1 |
| Rashidi, N | 1 |
| Nurgali, K | 1 |
| Apostolopoulos, V | 1 |
| Almulla, AF | 2 |
| Thipakorn, Y | 1 |
| Vasupanrajit, A | 1 |
| Tunvirachaisakul, C | 1 |
| Oxenkrug, G | 1 |
| Al-Hakeim, HK | 1 |
| Maes, M | 3 |
| Yun, Y | 1 |
| Zhang, Q | 1 |
| Zhao, W | 1 |
| Ma, T | 1 |
| Fan, H | 1 |
| Bai, L | 1 |
| Ma, B | 1 |
| Qi, S | 1 |
| Wang, Z | 1 |
| An, H | 1 |
| Yang, F | 1 |
| Feng, Z | 1 |
| Zheng, T | 1 |
| Dai, G | 1 |
| Wang, M | 1 |
| Zhou, L | 1 |
| Zheng, Y | 1 |
| Chen, G | 1 |
| Sales, PMG | 3 |
| Schrage, E | 3 |
| Coico, R | 3 |
| Pato, M | 3 |
| Michal, M | 1 |
| Schulz, A | 1 |
| Wild, PS | 1 |
| Koeck, T | 1 |
| Münzel, T | 1 |
| Schuster, AK | 1 |
| Strauch, K | 1 |
| Lackner, K | 1 |
| Süssmuth, SD | 2 |
| Niessen, HG | 2 |
| Borta, A | 1 |
| Allers, KA | 3 |
| Zahn, D | 1 |
| Beutel, ME | 1 |
| da Cunha, LL | 1 |
| Feter, N | 1 |
| Alt, R | 1 |
| Rombaldi, AJ | 1 |
| de Oliveira, T | 1 |
| Mouri, A | 2 |
| Hasegawa, M | 1 |
| Kunisawa, K | 1 |
| Saito, K | 2 |
| Nabeshima, T | 2 |
| Lin, P | 1 |
| Li, D | 1 |
| Shi, Y | 1 |
| Li, Q | 1 |
| Guo, X | 1 |
| Dong, K | 1 |
| Lou, X | 1 |
| Li, Z | 1 |
| Li, P | 1 |
| Jin, W | 1 |
| Chen, S | 1 |
| Sun, Y | 2 |
| Sun, J | 1 |
| Cheng, X | 1 |
| Ou, W | 1 |
| Chen, Y | 2 |
| Ju, Y | 1 |
| Ma, M | 1 |
| Qin, Y | 1 |
| Bi, Y | 1 |
| Liao, M | 1 |
| Liu, B | 1 |
| Liu, J | 1 |
| Zhang, Y | 1 |
| Li, L | 1 |
| Orrico-Sanchez, A | 1 |
| Guiard, BP | 1 |
| Manta, S | 1 |
| Callebert, J | 2 |
| Launay, JM | 3 |
| Louis, F | 1 |
| Paccard, A | 1 |
| Gruszczynski, C | 1 |
| Betancur, C | 1 |
| Vialou, V | 1 |
| Gautron, S | 1 |
| Colle, R | 1 |
| Masson, P | 1 |
| Verstuyft, C | 1 |
| Fève, B | 1 |
| Werner, E | 1 |
| Boursier-Neyret, C | 1 |
| Walther, B | 1 |
| David, DJ | 1 |
| Boniface, B | 1 |
| Falissard, B | 1 |
| Chanson, P | 1 |
| Corruble, E | 1 |
| Becquemont, L | 1 |
| Pu, J | 1 |
| Liu, Y | 1 |
| Zhang, H | 1 |
| Tian, L | 1 |
| Gui, S | 1 |
| Yu, Y | 1 |
| Chen, X | 1 |
| Yang, L | 1 |
| Ran, Y | 1 |
| Zhong, X | 2 |
| Xu, S | 1 |
| Song, X | 1 |
| Liu, L | 1 |
| Zheng, P | 1 |
| Wang, H | 1 |
| Xie, P | 1 |
| Drevets, W | 1 |
| Turecki, G | 1 |
| Li, QS | 1 |
| Ho, MF | 1 |
| Zhang, C | 1 |
| Zhang, L | 1 |
| Wei, L | 1 |
| Zhou, Y | 3 |
| Moon, I | 1 |
| Geske, JR | 1 |
| Choi, DS | 1 |
| Biernacka, J | 1 |
| Frye, M | 1 |
| Wen, Z | 1 |
| Karpyak, VM | 1 |
| Li, H | 2 |
| Weinshilboum, R | 1 |
| Öztürk, M | 1 |
| Yalın Sapmaz, Ş | 1 |
| Kandemir, H | 1 |
| Taneli, F | 1 |
| Aydemir, Ö | 1 |
| Marx, W | 1 |
| McGuinness, AJ | 1 |
| Rocks, T | 1 |
| Ruusunen, A | 1 |
| Cleminson, J | 1 |
| Walker, AJ | 1 |
| Gomes-da-Costa, S | 1 |
| Lane, M | 1 |
| Sanches, M | 1 |
| Diaz, AP | 1 |
| Tseng, PT | 1 |
| Lin, PY | 1 |
| Berk, M | 1 |
| Clarke, G | 2 |
| O'Neil, A | 1 |
| Jacka, F | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 3 |
| Quevedo, J | 2 |
| Soares, JC | 1 |
| Fernandes, BS | 1 |
| Branchi, I | 1 |
| Poggini, S | 1 |
| Capuron, L | 1 |
| Tamouza, R | 1 |
| Drexhage, HA | 1 |
| Penninx, BWJH | 3 |
| Pariante, CM | 2 |
| Pawlowski, T | 1 |
| Pawlak, D | 2 |
| Inglot, M | 1 |
| Zalewska, M | 1 |
| Marciniak, D | 1 |
| Bugajska, J | 1 |
| Janocha-Litwin, J | 1 |
| Malyszczak, K | 1 |
| Tsuchiyagaito, A | 1 |
| Smith, JL | 1 |
| El-Sabbagh, N | 1 |
| Zotev, V | 1 |
| Misaki, M | 1 |
| Al Zoubi, O | 1 |
| Kent Teague, T | 1 |
| Bodurka, J | 5 |
| Chiu, YC | 1 |
| Yang, BH | 1 |
| Yang, KC | 1 |
| Liu, MN | 1 |
| Hu, LY | 1 |
| Liou, YJ | 1 |
| Chan, LY | 1 |
| Chou, YH | 1 |
| Cathomas, F | 2 |
| Guetter, K | 1 |
| Seifritz, E | 2 |
| Klaus, F | 1 |
| Kaiser, S | 1 |
| Qiu, W | 1 |
| Go, KA | 1 |
| Lamers, Y | 1 |
| Galea, LAM | 1 |
| Kopra, E | 1 |
| Mondelli, V | 1 |
| Pariante, C | 1 |
| Nikkheslat, N | 1 |
| Milaneschi, Y | 1 |
| Beekman, ATF | 1 |
| Giltay, EJ | 1 |
| Keller, S | 1 |
| Schoevers, RA | 1 |
| Wurfel, BE | 4 |
| Drevets, WC | 5 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 3 |
| Morris, HM | 3 |
| Savitz, JB | 1 |
| Borsini, A | 1 |
| Alboni, S | 1 |
| Horowitz, MA | 1 |
| Tojo, LM | 1 |
| Cannazza, G | 1 |
| Su, KP | 1 |
| Zunszain, PA | 1 |
| Roomruangwong, C | 1 |
| Kanchanatawan, B | 1 |
| Sirivichayakul, S | 1 |
| Anderson, G | 1 |
| Duleu, S | 1 |
| Geffard, M | 1 |
| Sorgdrager, FJH | 1 |
| Doornbos, B | 2 |
| de Jonge, P | 2 |
| Kema, IP | 2 |
| Leonard, BE | 1 |
| DeWitt, SJ | 1 |
| Bradley, KA | 2 |
| Lin, N | 1 |
| Yu, C | 1 |
| Gabbay, V | 5 |
| Duan, KM | 1 |
| Ma, JH | 1 |
| Wang, SY | 1 |
| Yu, H | 1 |
| Liu, D | 1 |
| Ray, B | 1 |
| Neavin, DR | 1 |
| Zhang, J | 1 |
| Athreya, AP | 1 |
| Biernacka, JM | 1 |
| Bobo, WV | 1 |
| Hall-Flavin, DK | 1 |
| Skime, MK | 1 |
| Zhu, H | 1 |
| Jenkins, GD | 1 |
| Batzler, A | 1 |
| Kalari, KR | 1 |
| Boakye-Agyeman, F | 1 |
| Matson, WR | 1 |
| Bhasin, SS | 1 |
| Mushiroda, T | 1 |
| Nakamura, Y | 1 |
| Kubo, M | 1 |
| Iyer, RK | 1 |
| Frye, MA | 2 |
| Kaddurah-Daouk, R | 1 |
| Weinshilboum, RM | 1 |
| Kuwano, N | 1 |
| Kato, TA | 1 |
| Setoyama, D | 1 |
| Sato-Kasai, M | 1 |
| Shimokawa, N | 1 |
| Hayakawa, K | 1 |
| Ohgidani, M | 1 |
| Sagata, N | 1 |
| Kubo, H | 1 |
| Kishimoto, J | 1 |
| Kang, D | 1 |
| Kanba, S | 1 |
| Wu, Y | 1 |
| Mai, N | 1 |
| Wen, Y | 1 |
| Shang, D | 1 |
| Hu, L | 1 |
| Chen, B | 1 |
| Zhang, M | 1 |
| Ning, Y | 2 |
| Doolin, K | 1 |
| Pleiner, S | 1 |
| Liesener, A | 1 |
| Farrell, C | 1 |
| Tozzi, L | 1 |
| O'Hanlon, E | 1 |
| Roddy, D | 1 |
| Frodl, T | 2 |
| Harkin, A | 2 |
| O'Keane, V | 1 |
| Pompili, M | 1 |
| Lionetto, L | 1 |
| Curto, M | 1 |
| Forte, A | 1 |
| Erbuto, D | 1 |
| Montebovi, F | 1 |
| Seretti, ME | 1 |
| Berardelli, I | 1 |
| Serafini, G | 1 |
| Innamorati, M | 1 |
| Amore, M | 1 |
| Baldessarini, RJ | 1 |
| Girardi, P | 1 |
| Simmaco, M | 1 |
| Rudzki, L | 1 |
| Ostrowska, L | 1 |
| Małus, A | 1 |
| Pawlak, K | 1 |
| Waszkiewicz, N | 1 |
| Szulc, A | 1 |
| Zheng, W | 1 |
| Liu, W | 1 |
| Wang, C | 1 |
| Zhan, Y | 1 |
| Chen, L | 1 |
| Barone, P | 1 |
| Myint, AM | 6 |
| Bondy, B | 1 |
| Baghai, TC | 1 |
| Eser, D | 1 |
| Nothdurfter, C | 1 |
| Schüle, C | 1 |
| Zill, P | 1 |
| Müller, N | 3 |
| Rupprecht, R | 1 |
| Schwarz, MJ | 3 |
| Quak, J | 1 |
| Roest, AM | 1 |
| Duivis, HE | 1 |
| Vogelzangs, N | 1 |
| Nolen, WA | 1 |
| Penninx, BW | 1 |
| Smith, CM | 1 |
| Victor, TA | 3 |
| Bellgowan, PS | 1 |
| Yang, JJ | 1 |
| Wang, N | 1 |
| Shi, JY | 1 |
| Yu, HY | 1 |
| Hashimoto, K | 1 |
| Dahl, J | 1 |
| Andreassen, OA | 1 |
| Verkerk, R | 2 |
| Malt, UF | 1 |
| Sandvik, L | 1 |
| Brundin, L | 1 |
| Ormstad, H | 1 |
| Case, JA | 1 |
| Khan, O | 1 |
| Ricart, T | 1 |
| Hanna, A | 1 |
| Alonso, CM | 2 |
| Réus, GZ | 1 |
| Jansen, K | 1 |
| Titus, S | 1 |
| Fuertig, R | 1 |
| Sigrist, H | 1 |
| Newman, GN | 1 |
| Hoop, V | 1 |
| Bizzozzero, M | 1 |
| Mueller, A | 1 |
| Luippold, A | 1 |
| Ceci, A | 1 |
| Hengerer, B | 1 |
| Fontana, A | 1 |
| Pryce, CR | 1 |
| Meier, TB | 2 |
| McIntosh, SA | 1 |
| Zanos, P | 1 |
| Piantadosi, SC | 1 |
| Wu, HQ | 1 |
| Pribut, HJ | 1 |
| Dell, MJ | 1 |
| Can, A | 1 |
| Snodgrass, HR | 1 |
| Zarate, CA | 1 |
| Schwarcz, R | 1 |
| Gould, TD | 1 |
| Teraishi, T | 1 |
| Hori, H | 1 |
| Sasayama, D | 1 |
| Matsuo, J | 1 |
| Ogawa, S | 1 |
| Ota, M | 1 |
| Hattori, K | 1 |
| Kajiwara, M | 1 |
| Higuchi, T | 1 |
| Kunugi, H | 1 |
| Georgin-Lavialle, S | 1 |
| Moura, DS | 1 |
| Salvador, A | 1 |
| Chauvet-Gelinier, JC | 1 |
| Damaj, G | 1 |
| Côté, F | 1 |
| Soucié, E | 1 |
| Chandesris, MO | 1 |
| Barète, S | 1 |
| Grandpeix-Guyodo, C | 1 |
| Bachmeyer, C | 1 |
| Alyanakian, MA | 1 |
| Aouba, A | 1 |
| Lortholary, O | 1 |
| Dubreuil, P | 1 |
| Teyssier, JR | 1 |
| Trojak, B | 1 |
| Haffen, E | 1 |
| Vandel, P | 1 |
| Bonin, B | 1 |
| Hermine, O | 1 |
| Gaillard, R | 1 |
| Bhat, M | 1 |
| Schuppe-Koistinen, I | 1 |
| Jungholm, O | 1 |
| Johansson, AG | 1 |
| Landén, M | 1 |
| Sellgren, CM | 1 |
| Young, KD | 1 |
| Velasquez, S | 1 |
| Rappaport, J | 1 |
| Won, E | 1 |
| Kim, YK | 1 |
| Tashiro, T | 1 |
| Murakami, Y | 1 |
| Imamura, Y | 1 |
| Yamamoto, Y | 1 |
| Fitzgerald, P | 1 |
| Cassidy Eugene, M | 1 |
| Scully, P | 1 |
| Barry, S | 1 |
| Quigley Eamonn, MM | 1 |
| Shanahan, F | 1 |
| Cryan, J | 1 |
| Dinan Timothy, G | 1 |
| Van Gool, AR | 1 |
| Fekkes, D | 1 |
| Bannink, M | 1 |
| Sleijfer, S | 1 |
| Kruit, WH | 1 |
| van der Holt, B | 1 |
| Scharpé, S | 1 |
| Eggermont, AM | 1 |
| Stoter, G | 1 |
| Hengeveld, MW | 1 |
| Laugeray, A | 1 |
| Surget, A | 1 |
| Belzung, C | 1 |
| Barone, PR | 1 |
| Klein, RG | 1 |
| Katz, Y | 1 |
| Mendoza, S | 1 |
| Guttman, LE | 1 |
| Babb, JS | 1 |
| Hirsch, GS | 1 |
| Liebes, L | 2 |
| Oxenkrug, GF | 2 |
| Claes, S | 1 |
| Domschke, K | 1 |
| Del-Favero, J | 1 |
| Entrich, K | 1 |
| Engelborghs, S | 1 |
| De Deyn, P | 1 |
| Mueller, N | 1 |
| Baune, B | 1 |
| Rothermundt, M | 1 |
| Sublette, ME | 1 |
| Galfalvy, HC | 1 |
| Fuchs, D | 1 |
| Lapidus, M | 1 |
| Grunebaum, MF | 1 |
| Oquendo, MA | 1 |
| Mann, JJ | 1 |
| Postolache, TT | 1 |
| Steiner, J | 1 |
| Bogerts, B | 1 |
| Sarnyai, Z | 1 |
| Walter, M | 1 |
| Gos, T | 1 |
| Bernstein, HG | 1 |
| Ely, BA | 1 |
| Babb, J | 1 |
| Krause, DL | 1 |
| Riedel, M | 1 |
| Weidinger, E | 1 |
| Hughes, MM | 1 |
| Carballedo, A | 1 |
| McLoughlin, DM | 1 |
| Amico, F | 1 |
| Connor, TJ | 1 |
| Shader, RI | 1 |
| Miura, H | 1 |
| Ozaki, N | 1 |
| Sawada, M | 1 |
| Isobe, K | 1 |
| Ohta, T | 1 |
| Nagatsu, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacodynamics and Pharmacokinetics of Citalopram and Escitalopram[NCT00613470] | Phase 1 | 927 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Effects of 3-month Probiotic Mix Supplementation (L. Helveticus R-0052, B. Longum R-0175) on Gut Microbiota and Metabolome, Endocannabinoid and Immune Systems Activation, Along With Symptoms of Fatigue in Professional Dancers[NCT05567653] | 60 participants (Anticipated) | Interventional | 2022-09-21 | Recruiting | |||
| A Longitudinal Study of Inflammatory Pathways in Depression[NCT04159207] | 160 participants (Anticipated) | Observational | 2019-10-01 | Recruiting | |||
| Investigating Brain Abnormalities in People With Knee Osteoarthritis Using MRI: a Nociplastic Pain Mechanism Based Assessment[NCT05986513] | 66 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Kynurenine Pathway Metabolites as Novel Translational Biological Markers of Irritable Bowel Syndrome: Relationship to Gastrointestinal Function, Cognition and Co-morbid Depression[NCT01304355] | 85 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial[NCT02155972] | Phase 2 | 16 participants (Actual) | Interventional | 2013-05-31 | Terminated (stopped due to The trial was terminated because of inability to recruit the needed number of participants) | ||
| A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia[NCT02074319] | Phase 1 | 92 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for kynurenine and Depression, Involutional
| Article | Year |
|---|---|
COVID-19, Oxidative Stress, and Neuroinflammation in the Depression Route.
Topics: COVID-19; Depression; Depressive Disorder, Major; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infl | 2022 |
The role and mechanism of tryptophan - kynurenine metabolic pathway in depression.
Topics: Depression; Depressive Disorder, Major; Humans; Inflammation; Kynurenine; Metabolic Networks and Pat | 2023 |
The Role of Tryptophan Metabolites in Neuropsychiatric Disorders.
Topics: Depressive Disorder, Major; Humans; Kynurenine; Proteomics; Serotonin; Tryptophan | 2022 |
The Tryptophan Catabolite or Kynurenine Pathway in a Major Depressive Episode with Melancholia, Psychotic Features and Suicidal Behaviors: A Systematic Review and Meta-Analysis.
Topics: Albumins; Amino Acids; Depressive Disorder, Major; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kyn | 2022 |
Associations between the kynurenine pathway and the brain in patients with major depressive disorder-A systematic review of neuroimaging studies.
Topics: Brain; Depressive Disorder, Major; Diffusion Tensor Imaging; Humans; Kynurenine; Magnetic Resonance | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Effects of exercise training on inflammatory, neurotrophic and immunological markers and neurotransmitters in people with depression: A systematic review and meta-analysis.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; Depressive Disorder, Ma | 2023 |
The kynurenine pathway in major depressive disorder under different disease states: A systematic review and meta-analysis.
Topics: Biomarkers; Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Quinolinic A | 2023 |
An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Schizophrenia | 2021 |
The kynurenine pathway in major depression: What we know and where to next.
Topics: Brain; Depression; Depressive Disorder, Major; Humans; Kynurenine | 2021 |
Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Bipolar Disorder; Cytokines; Depressive Di | 2021 |
The role of tryptophan metabolism in postpartum depression.
Topics: Depression; Depression, Postpartum; Depressive Disorder, Major; Female; Humans; Kynurenine; Quinolin | 2018 |
The 'Yin' and the 'Yang' of the kynurenine pathway: excitotoxicity and neuroprotection imbalance in stress-induced disorders.
Topics: Animals; Brain; Cytokines; Depressive Disorder, Major; Excitatory Amino Acid Agents; Humans; Hypotha | 2019 |
Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.
Topics: Animals; Depressive Disorder, Major; Humans; Kynurenine; Metabolic Networks and Pathways | 2015 |
Stress, the Autonomic Nervous System, and the Immune-kynurenine Pathway in the Etiology of Depression.
Topics: Animals; Autonomic Nervous System; Depressive Disorder, Major; Humans; Kynurenine; Stress, Psycholog | 2016 |
Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later.
Topics: Adrenal Cortex Hormones; Animals; Biosynthetic Pathways; Cytokines; Depressive Disorder, Major; Envi | 2010 |
Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity.
Topics: Blood-Brain Barrier; Depressive Disorder, Major; Glutamic Acid; Humans; Inflammation; Kynurenine; Ne | 2012 |
The role of the kynurenine metabolism in major depression.
Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Humans; Inflammation; Kynurenine; Trypto | 2012 |
Kynurenines: from the perspective of major psychiatric disorders.
Topics: Animals; Bipolar Disorder; Depressive Disorder, Major; Humans; Kynurenine; Schizophrenia | 2012 |
Genetic and hormonal regulation of tryptophan kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging.
Topics: Aging; Animals; Cognition Disorders; Cytokines; Depressive Disorder, Major; Hormones; Humans; Kynure | 2007 |
A link between stress and depression: shifts in the balance between the kynurenine and serotonin pathways of tryptophan metabolism and the etiology and pathophysiology of depression.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Brain; Cytokines; Depression; Depressive Disord | 2008 |
1 trial available for kynurenine and Depression, Involutional
| Article | Year |
|---|---|
Probiotic Lactobacillus Plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: A double-blind, randomized, placebo controlled study.
Topics: Adult; Attention; Cognition; Combined Modality Therapy; Depressive Disorder, Major; Double-Blind Met | 2019 |
67 other studies available for kynurenine and Depression, Involutional
| Article | Year |
|---|---|
Investigation of the Relationship among Cortisol, Pro-inflammatory Cytokines, and the Degradation of Tryptophan into Kynurenine in Patients with Major Depression and Suicidal Behavior.
Topics: Cytokines; Depressive Disorder, Major; Humans; Hydrocortisone; Interleukin-1; Interleukin-12; Kynure | 2022 |
δ
Topics: Biomarkers; Depressive Disorder, Major; Heart Rate; Humans; Kynurenine; Quinolinic Acid; Reproducibi | 2021 |
Selective association of cytokine levels and kynurenine/tryptophan ratio with alterations in white matter microstructure in bipolar but not in unipolar depression.
Topics: Biomarkers; Bipolar Disorder; Cytokines; Depressive Disorder, Major; Humans; Kynurenine; Tryptophan; | 2022 |
Peripheral and central kynurenine pathway abnormalities in major depression.
Topics: Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Quinolinic Acid | 2022 |
Alterations in the kynurenine pathway and excitatory amino acid transporter-2 in depression with and without psychosis: Evidence of a potential astrocyte pathology.
Topics: Astrocytes; Depression; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Psychotic Di | 2022 |
Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Biomarkers; Depressive Disorder, Major; Dopamine; | 2022 |
Inflammation and serotonin deficiency in major depressive disorder: molecular docking of antidepressant and anti-inflammatory drugs to tryptophan and indoleamine 2,3-dioxygenases.
Topics: Anti-Inflammatory Agents; Antidepressive Agents; Depressive Disorder, Major; Humans; Indoleamine-Pyr | 2022 |
Left DLPFC activity is associated with plasma kynurenine levels and can predict treatment response to escitalopram in major depressive disorder.
Topics: Depressive Disorder, Major; Escitalopram; Humans; Kynurenine; Magnetic Resonance Imaging; Prefrontal | 2022 |
Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies.
Topics: Animals; Antioxidants; Depression; Depressive Disorder, Major; Disease Models, Animal; Humans; Kelch | 2022 |
C-Reactive protein and the kynurenic acid to quinolinic acid ratio are independently associated with white matter integrity in major depressive disorder.
Topics: C-Reactive Protein; Depressive Disorder, Major; Diffusion Tensor Imaging; Humans; Kynurenic Acid; Ky | 2022 |
A combination of neuroimaging and plasma metabolomic analysis suggests inflammation is associated with white matter structural connectivity in major depressive disorder.
Topics: Brain; Depressive Disorder, Major; Humans; Inflammation; Kynurenine; Lysophosphatidylcholines; Magne | 2022 |
The Tryptophan Catabolite or Kynurenine Pathway's Role in Major Depression.
Topics: Depression; Depressive Disorder, Major; Humans; Kynurenine; Tryptophan | 2022 |
Relationship between the tryptophan-kynurenine pathway and painful physical symptoms in patients with major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Pain; Quinolinic Acid; Serotonin; Ta | 2022 |
Tryptophan catabolites and depression in the general population: results from the Gutenberg Health Study.
Topics: Biomarkers; C-Reactive Protein; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Tryp | 2023 |
Stress and Kynurenine-Inflammation Pathway in Major Depressive Disorder.
Topics: Depressive Disorder, Major; Dioxygenases; Humans; Inflammation; Kynurenine; Quality of Life; Tryptop | 2023 |
[Diagnoses and new therapeutic strategy focused on physiological alteration of tryptophan metabolism].
Topics: alpha7 Nicotinic Acetylcholine Receptor; Antidepressive Agents; Depressive Disorder, Major; Humans; | 2023 |
Dysbiosis of the Gut Microbiota and Kynurenine (Kyn) Pathway Activity as Potential Biomarkers in Patients with Major Depressive Disorder.
Topics: Biomarkers; China; Depressive Disorder, Major; Dysbiosis; Gastrointestinal Microbiome; Humans; Kynur | 2023 |
Organic cation transporter 2 contributes to SSRI antidepressant efficacy by controlling tryptophan availability in the brain.
Topics: Anhedonia; Animals; Antidepressive Agents; Brain; Corticosterone; Depressive Disorder, Major; Fluoxe | 2023 |
Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: A case-control study.
Topics: 3-Hydroxyanthranilic Acid; Adult; Case-Control Studies; Cohort Studies; Depressive Disorder, Major; | 2020 |
The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
Topics: Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Humans; Kynurenic Acid; Kynurenine | 2020 |
TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response.
Topics: Acamprosate; Alcohol Drinking; Alcoholism; Depressive Disorder, Major; Humans; Induced Pluripotent S | 2021 |
The role of the kynurenine pathway and quinolinic acid in adolescent major depressive disorder.
Topics: Adolescent; Cross-Sectional Studies; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; | 2021 |
Brain-immune crosstalk in the treatment of major depressive disorder.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Humans; Kynurenine; Neuronal Plasticity | 2021 |
The role of anthranilic acid in the increase of depressive symptoms and major depressive disorder during treatment for hepatitis C with pegylated interferon-α2a and oral ribavirin.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Depression; Depressive Disorder, Major; Female; He | 2021 |
Real-time fMRI neurofeedback amygdala training may influence kynurenine pathway metabolism in major depressive disorder.
Topics: Amygdala; Depressive Disorder, Major; Humans; Kynurenine; Magnetic Resonance Imaging; Neurofeedback | 2021 |
A study of tryptophan, kynurenine and serotonin transporter in first-episode drug-naïve major depressive disorder.
Topics: Depressive Disorder, Major; Humans; Kynurenine; Pharmaceutical Preparations; Serotonin Plasma Membra | 2021 |
Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder.
Topics: Adult; Case-Control Studies; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Female; H | 2021 |
Postpartum corticosterone and fluoxetine shift the tryptophan-kynurenine pathway in dams.
Topics: Animals; Corticosterone; Depression, Postpartum; Depressive Disorder, Major; Female; Fluoxetine; Hum | 2021 |
The association between plasma tryptophan catabolites and depression: The role of symptom profiles and inflammation.
Topics: Depression; Depressive Disorder, Major; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Rescue of IL-1β-induced reduction of human neurogenesis by omega-3 fatty acids and antidepressants.
Topics: Antidepressive Agents; Cell Culture Techniques; Cytokines; Depression; Depressive Disorder, Major; D | 2017 |
IgM-mediated autoimmune responses to oxidative specific epitopes, but not nitrosylated adducts, are significantly decreased in pregnancy: association with bacterial translocation, perinatal and lifetime major depression and the tryptophan catabolite (TRYC
Topics: Adult; Autoimmunity; Bacterial Translocation; Biomarkers; Cytokines; Depression, Postpartum; Depress | 2017 |
The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls.
Topics: Adult; Antidepressive Agents; Chromatography, High Pressure Liquid; Depression; Depressive Disorder, | 2017 |
Major Depression as a Neuroprogressive Prelude to Dementia: What Is the Evidence?
Topics: Brain; Cytokines; Dementia; Depressive Disorder, Major; Humans; Inflammation; Kynurenine; Oxidative | 2017 |
A pilot resting-state functional connectivity study of the kynurenine pathway in adolescents with depression and healthy controls.
Topics: Adolescent; Anhedonia; Brain; Case-Control Studies; Depressive Disorder, Major; Female; Gray Matter; | 2018 |
Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics.
Topics: Basic Helix-Loop-Helix Transcription Factors; beta-Defensins; Biomarkers; Depressive Disorder, Major | 2018 |
Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for first-episode drug-naïve patients with major depressive disorder: An exploratory pilot case-control study.
Topics: Adult; Biomarkers; Case-Control Studies; Depressive Disorder, Major; Female; Humans; Kynurenine; Lip | 2018 |
Kynurenine pathway changes in late-life depression.
Topics: Adult; Age Factors; Aged; Depressive Disorder, Major; Female; Humans; Kynurenic Acid; Kynurenine; Ma | 2018 |
Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes.
Topics: Adult; Biomarkers; C-Reactive Protein; CA1 Region, Hippocampal; CA2 Region, Hippocampal; CA3 Region, | 2018 |
Tryptophan and Kynurenine Metabolites: Are They Related to Depression?
Topics: Adult; Bipolar Disorder; Case-Control Studies; Depressive Disorder, Major; Female; Humans; Hydroxyin | 2019 |
Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder.
Topics: Adult; Chromatography, Liquid; Cognition; Cross-Sectional Studies; Depression; Depressive Disorder, | 2019 |
Tryptophan metabolism and immunogenetics in major depression: a role for interferon-γ gene.
Topics: Adult; Aged; Depressive Disorder, Major; Female; Humans; Hydroxyindoleacetic Acid; Immunogenetics; I | 2013 |
Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?
Topics: Adolescent; Adult; Aged; Case-Control Studies; Depression; Depressive Disorder, Major; Female; Human | 2014 |
Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder.
Topics: Adult; Amygdala; Anhedonia; Brain-Derived Neurotrophic Factor; C-Reactive Protein; Depressive Disord | 2015 |
Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Topics: Antidepressive Agents; Biomarkers, Pharmacological; Depressive Disorder, Major; Depressive Disorder, | 2015 |
Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers.
Topics: Adolescent; Adult; Biomarkers; Chromatography, High Pressure Liquid; Cytokines; Depressive Disorder, | 2015 |
The role of the kynurenine pathway in suicidality in adolescent major depressive disorder.
Topics: Adolescent; Anhedonia; Biomarkers; Depressive Disorder, Major; Female; Humans; Kynurenine; Male; Sui | 2015 |
CD40-TNF activation in mice induces extended sickness behavior syndrome co-incident with but not dependent on activation of the kynurenine pathway.
Topics: Animals; Antibodies, Monoclonal; Behavior, Animal; CD40 Antigens; CD40 Ligand; Conditioning, Psychol | 2015 |
Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder.
Topics: Adult; Anhedonia; Biomarkers; Corpus Striatum; Depressive Disorder, Major; Female; Humans; Kynurenic | 2015 |
The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Depressive Disorder, Major; Glycine; Hindlim | 2015 |
(13)C-tryptophan breath test detects increased catabolic turnover of tryptophan along the kynurenine pathway in patients with major depressive disorder.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antidepressive Agents; Area Under Curve; Br | 2015 |
Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Topics: Adult; Brain; C-Reactive Protein; Case-Control Studies; Cerebral Cortex; Depressive Disorder, Major; | 2016 |
Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis.
Topics: Depression; Depressive Disorder, Major; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflam | 2016 |
Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients.
Topics: Adult; Chromatography, High Pressure Liquid; Cohort Studies; Cytokines; Depressive Disorder, Major; | 2016 |
Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression.
Topics: Adult; Depressive Disorder, Major; Female; Hippocampus; Humans; Kynurenic Acid; Kynurenine; Magnetic | 2016 |
Inflammasome Activation in Major Depressive Disorder: A Pivotal Linkage Between Psychological Stress, Purinergic Signaling, and the Kynurenine Pathway.
Topics: Depressive Disorder, Major; Humans; Inflammasomes; Kynurenine; Stress, Psychological; Tryptophan | 2016 |
Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Depressive Disorder, Major; Disease Models, Ani | 2017 |
Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity.
Topics: Adult; Anxiety Disorders; Chromatography, High Pressure Liquid; Comorbidity; Depressive Disorder, Ma | 2008 |
Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity.
Topics: Adult; Anxiety Disorders; Chromatography, High Pressure Liquid; Comorbidity; Depressive Disorder, Ma | 2008 |
Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity.
Topics: Adult; Anxiety Disorders; Chromatography, High Pressure Liquid; Comorbidity; Depressive Disorder, Ma | 2008 |
Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity.
Topics: Adult; Anxiety Disorders; Chromatography, High Pressure Liquid; Comorbidity; Depressive Disorder, Ma | 2008 |
Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon-alpha: course and relationship with psychiatric status.
Topics: Adult; Aged; Brain; Carcinoma, Renal Cell; Depressive Disorder, Major; Dose-Response Relationship, D | 2008 |
Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression.
Topics: Animals; Brain; Chronic Disease; Depressive Disorder, Major; Disease Models, Animal; Hydroxyindoleac | 2010 |
The possible role of the kynurenine pathway in adolescent depression with melancholic features.
Topics: 3-Hydroxyanthranilic Acid; Adolescent; Child; Cytokines; Depressive Disorder; Depressive Disorder, M | 2010 |
The kynurenine pathway in major depression: haplotype analysis of three related functional candidate genes.
Topics: Adult; Depressive Disorder, Major; Female; Gene Frequency; Genetic Predisposition to Disease; Haplot | 2011 |
Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Cytokines; Depressive Disorder, Major; Duloxetine Hy | 2011 |
The possible role of the kynurenine pathway in anhedonia in adolescents.
Topics: Adolescent; Anhedonia; Biomarkers; Depressive Disorder, Major; Female; Humans; Kynurenine; Male; Neu | 2012 |
Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients.
Topics: Adult; Antidepressive Agents; Blood Cells; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Cytokines; | 2012 |
Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation.
Topics: Adult; Biomarkers; C-Reactive Protein; Chromatography, High Pressure Liquid; Cytokines; Depressive D | 2012 |
Kynurenine--an old pathway retraced.
Topics: Animals; Depressive Disorder, Major; Humans; Hydrolases; Inflammation; Interferons; Kynurenine; orth | 2006 |